Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial Cancer

European Urology

Volumn 52, Issue 4, 2007, Pages 1106-1114

  Abe, Takashige ^a   Shinohara, Nobuo ^a   Harabayashi, Toru ^a   Sazawa, Ataru ^a   Maruyama, Satoru ^a   Suzuki, Shin ^b   Nonomura, Katsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOHNAN HOSPITAL   (Japan)

Author keywords

Chemotherapy; Metastasectomy; Prognostic factor; Urothelial cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; NEDAPLATIN; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HAZARD ASSESSMENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; LOBECTOMY; LYMPHADENECTOMY; MALE; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; UROGENITAL TRACT TUMOR;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; UROLOGIC NEOPLASMS;

EID: 34548210495     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.02.052     Document Type: Article

References (23)

1. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133 (1985) 403-407
2. Scher H.I. Should single agents be standard therapy for urothelial tract tumors?. J Clin Oncol 7 (1989) 694-697
3. Roth B.J., and Bajorin D.F. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153 (1995) 894-900
4. Sternberg C.N. The treatment of advanced bladder cancer. Ann Oncol 6 (1995) 113-126
5. Loehrer Sr. P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066-1073
6. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050-1055
7. Kuroda M., Kotake T., Akaza H., Hinotsu S., and Kakizoe T. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. Jpn J Clin Oncol 28 (1998) 497-501
8. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17 (2000) 3068-3077
9. Bellmunt J., Albanell J., Paz-Ares L., et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95 (2002) 751-757
10. Bajorin D.F., McCaffrey J.A., Dodd P.M., et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 88 (2000) 1671-1678
11. Galsky M.D. The role of taxanes in the management of bladder cancer. Oncologist 10 (2005) 792-798
12. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
13. Bellmunt J., Guillem V., Paz-Ares L., et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 18 (2000) 3247-3255
14. Sternberg C.N., Calabro F., Pizzocaro G., Marini L., Schnetzer S., and Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92 (2001) 2993-2998
15. Hussain M., Vaishampayan U., Du W., Redman B., and Smith D.C. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19 (2001) 2527-2533
16. Shinohara N., Harabayashi T., Suzuki S., et al. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. Cancer Chemother Pharmacol 58 (2006) 402-407
17. Sengelov L., Kamby C., Lund B., and Engelholm S.A. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 16 (1998) 3392-3397
18. Siefker-Radtke A.O., Walsh G.L., Pisters L.L., et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171 (2004) 145-148
19. Dodd P.M., McCaffrey J.A., Herr H., et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17 (1999) 2546-2552
20. Miller R.S., Freiha F.S., Reese J.H., Ozen H., and Torti F.M. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 150 (1993) 65-69
21. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 (1999) 3173-3181
22. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (1997) 2564-2569
23. Cowles R.S., Johnson D.E., and McMurtrey M.J. Long-term results following thoracotomy for metastatic bladder cancer. Urology 20 (1982) 390-392